Skip to search formSkip to main contentSkip to account menu

talabostat

Known as: [(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid, valinyl-boroproline 
A small molecule with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

Boronic AcidsDipeptides
NCIt Antineoplastic Agent TerminologyPT-100 dipeptide

Narrower (1)

PT 100

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Specificity of inhibitors and frequency of expression of target proteins used to study cartilage invasion by rheumatoid arthritis synovial fibroblasts: comment on the article by Ospelt et al.
To the Editor: We read with great interest the recent article by Ospelt et al, in which the authors evaluated the influence of L… 
2008
2008
Pediatric phase I trial design using a pharmacodynamic marker as the primary endpoint
10027 Background: The optimal dose of less toxic molecularly targeted agents should be defined by target modulation rather than… 
2006
2006
Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma.
8040 Background: Talabostat (TAL) is an oral inhibitor of dipeptidyl peptidases such as fibroblast activation protein found on… 
2006
2006
Phase II study of talabostat and rituximab in fludarabine/rituximab-resistant or refractory patients with CLL.
6598 Background: Talabostat (TAL) is an orally administered small molecule inhibitor of dipeptidyl peptidases such as CD26 and… 
2006
2006
Reduction of murine osteosarcoma lung metastases using the dipeptidyl peptidase inhibitor talabostat.
9009 Background: Dipeptidyl peptidases comprise a family of serine proteases that includes the genes dipeptidyl peptidase IV (DPP… 
2006
2006
Characterization of innate effector cells involved in the anti-tumor activity of talabostat (PT-100)
4659 Talabostat (PT-100) is L-valinyl-L-boroproline, an orally available anti-tumor agent. In immunocompetent and immunodeficient… 
2006
2006
Talabostat augments IL-1β and IL-1α production from peripheral blood monocytes isolated from healthy donors.
A8 Talabostat (L-valine-L-boroproline), an orally active, potent inhibitor of dipeptidyl peptidases, is in clinical trials for… 
2005
2005
Phase 2 trial of talabostat and docetaxel in patients with stage IIIb/IV NSCLC
7120 Background: Talabostat (T) is an oral inhibitor of dipeptidyl peptidases such as fibroblast activation protein found on the… 
2004
2004
Phase 1 Rising Multiple-Dose Study of Talabostat (PT-100) in Healthy Subjects.
Background: Talabostat (PT-100) is an orally available small molecule that competitively inhibits dipeptidyl peptidases such as… 
2003
2003
Procedes et compositions ayant trait a des composes d'isoleucine boroproline
L'invention concerne une methode de traitement de patients souffrant, entre autres, d'une proliferation cellulaire anormale ou d… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)